On February 8, 2018 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, reported that Matthew R. Patterson, President and Chief Executive Officer, will present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY (Press release, Audentes Therapeutics, FEB 8, 2018, View Source;p=RssLanding&cat=news&id=2331287 [SID1234523819]). The presentation is scheduled for Thursday, February 15, 2018, at 10:30 am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. A replay of the live webcast will be available on the Audentes website for approximately 30 days following the conference.

On February 8, 2018 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported that it will present at the Leerink Partners 7th Annual Global Healthcare Conference at 11:30 a.m. ET on Thursday, Feb. 15, 2018, in New York City (Press release, Neurocrine Biosciences, FEB 8, 2018, View Source;p=RssLanding&cat=news&id=2331383 [SID1234523860]). Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and may be accessed on the Company’s website under Investors at View Source A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Cardinal Health has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Cardinal Health, 2018, FEB 8, 2018, View Source [SID1234523809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 8, 2018 Bristol-Myers Squibb Company (NYSE: BMY) will take part in the Leerink Annual Global Healthcare Conference on Thursday, February 15, 2018, in New York (Press release, Bristol-Myers Squibb, FEB 8, 2018, View Source [SID1234523820]). Giovanni Caforio, chief executive officer and chairman, will answer questions about the company at 9:00 a.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source An archived edition of the session will be available later that day.

On February 8, 2018 Perrigo Company plc (NYSE; TASE: PRGO) reported that it will release its fourth quarter and calendar year 2017 financial results on Tuesday, February 27, 2018 (Press release, Perrigo Company, FEB 8, 2018, View Source [SID1234523861]). The Company will also host a conference call beginning at 9:30 a.m. (EST).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at View Source or by phone at 877-248-9413, International 973-582-2737, and reference ID #2088843. A taped replay of the call will be available beginning at approximately 12:00 p.m. (EST) Tuesday, February 27, until midnight Friday, March 9, 2018. To listen to the replay, dial 800-585-8367, International 404-537-3406, and use access code 2088843.